Activity

Total Records: 5

Added Webinar Recording -

Synterex, Inc. -

65 days ago

Automation & AI in Medical Communications, Pt 2: Practical Applications & Case Studies

Elizabeth P. from Synterex, Inc.

In Part 2 of our AI & Automation series, we delve deeper into practical case studies and real-world applications of AI in medical communications. Join Synterex as we explore the next phase of AI adoption, focusing on automating business processes, optimizing medical writing workflows, and leveraging AI for better stakeholder engagement.

Watch now to learn:
How to build a business information library for efficient content generation
The role of AI-driven automation in medical writing and regulatory documentation
Best practices for explaining AI adoption to stakeholders and clients
Examples of using automation to streamline business processes

Added Webinar Recording -

Synterex, Inc. -

65 days ago

Automation & AI in Medical Communications, Pt 1: Balancing Risk and Value

Elizabeth P. from Synterex, Inc.

Synterex partnered with MarketBeam to host "Automation & AI to Solve Business Problems in Medical Communications" in June 2024.

Discover how AI and automation are transforming medical communications in this insightful webinar hosted by Synterex. From balancing regulatory risks to optimizing business practices, this webinar delves into the practical applications of AI across the medical writing landscape.

Watch now to learn:
How AI and automation can streamline medical writing processes
Best practices for AI compliance and governance
Real-world case studies on AI’s impact on business efficiency
Key insights into managing AI-driven risks in clinical and regulatory documentation

Added Whitepaper -

Synterex, Inc. -

65 days ago

(White Paper) This One’s for the Children: Progress in Pediatric Drug Development in the United States

Elizabeth P. from Synterex, Inc.

Prior to the FD&C Act, pharmaceutical companies were not required to provide proof of drug safety or a disclosure of all active ingredients. Since then, all new drugs undergo an intensive review process by the Food and Drug Administration (FDA), and ever-evolving guidance and regulations ensure that both new drugs and those with updated characteristics, such as dosing, delivery, and expanded indications, are safe and effective for the intended populations. A gap remains, however, for drug investigations including and targeted for children of varying ages.

Download and read now for more insights!

Added Whitepaper -

Synterex, Inc. -

65 days ago

(White Paper) The Road to Representation in Clinical Research

Elizabeth P. from Synterex, Inc.

Innovative development of human drugs, biologics, and medical devices (medical products) and their quick advancement through the United States Food and Drug Administration (FDA) approval pipeline is necessary to improve the lives of patients. It is also imperative for sponsors to consider diversity when enrolling study participants throughout the clinical development pipeline to adequately represent the population of patients who have a disease or condition.

Download and read now for more insights!

Added to List -

Synterex, Inc. -

303 days ago

Andy S.